Comparative assessment of the incidence and severity of tardive dyskinesia in patients receiving aripiprazole or haloperidol for the treatment of schizophrenia: A post hoc analysis

Journal of Clinical Psychiatry

Volumn 68, Issue 12, 2007, Pages 1901-1906

  Miller, Del D ^a   Eudicone, James M ^b   Pikalov, Andrei ^c   Kim, Edward ^b  

^a UNIVERSITY OF IOWA   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; HALOPERIDOL;

ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INCIDENCE; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOPHRENIA; TARDIVE DYSKINESIA; TREATMENT OUTCOME;

EID: 38049005307     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v68n1210     Document Type: Article

References (65)

1. Casey D. Spontaneous and tardive dyskinesias: clinical and laboratory studies. J Clin Psychiatry 1985;46:42-47
2. Casey DE. Tardive dyskinesia. In: Meltzer HY, ed. Psychopharmacology: The Third Generation of Progress. New York, NY: Raven Press; 1987:1411-1419
3. Chakos MH, Alvir JMJ, Woerner MG, et al. Incidence and correlates of tardive dyskinesia in first episode schizophrenia. Arch Gen Psychiatry 1996;53:313-319
4. Chatterjee A, Chakos M, Koreen A, et al. Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients. Am J Psychiatry 1995;152:1724-1729
5. Margolese HC, Chouinard G, Kolivakis TT, et al. Tardive dyskinesia in the era of typical and atypical antipsychotics, pt 1: pathophysiology and mechanisms of induction. Can J Psychiatry 2005;50:541-547
6. Margolese HC, Chouinard G, Kolivakis TT, et al. Tardive dyskinesia in the era of typical and atypical antipsychotics, pt 2: incidence and management strategies in patients with schizophrenia. Can J Psychiatry 2005;50:703-714
7. Woerner MG, Alvir JM, Saltz BL, et al. Prospective study of tardive dyskinesia in the elderly: rates and risk factors. Am J Psychiatry 1998;155:1521-1528
8. Kane JM, Woerner M, Liebeiman J. Tardive dyskinesia: prevalence, incidence, and risk factors. J Clin Psychopharmacol 1988;8(suppl 4):52S-56S
9. Miller DD, McEvoy JP, Davis SM, et al. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophr Res 2005;80:33-43
10. Nasrallah HA. Focus on lower risk of tardive dyskinesia with atypical antipsychotics. Ann Clin Psychiatry 2006;18:57-62
11. Saltz BL, Woerner MG, Kane JM, et al. Prospective study of tardive dyskinesia incidence in the elderly. JAMA 1991;266:2402-2406
12. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004;161:414-425
13. Eberhard J, Lindstrom E, Levander S. Tardive dyskinesia and antipsychotics: a 5-year longitudinal study of frequency, correlates and course. Int Clin Psychopharmacol 2006;21:35-42
14. Gebhardt S, Hartling F, Hanke M, et al. Prevalence of movement disorders in adolescent patients with schizophrenia and in relationship to predominantly atypical antipsychotic treatment. Eur Child Adolesc Psychiatry 2006;15:371-382
15. Lee C, Wu KH, Habil H, et al. Treatment with olanzapine, risperidone or typical antipsychotic drugs in Asian patients with schizophrenia. Aust N Z J Psychiatry 2006;40:437-445
16. Haro JM, Salvador-Curulla L. The SOHO (Schizophrenia Outpatient Health Outcome) study: implications for the treatment of schizophrenia. CNS Drugs 2006;20:293-301
17. Dolder CR, Jeste DV. Incidence of tardive dyskinesia with typical versus atypical antipsychotics in very high risk patients. Biol Psychiatry 2003;53:1142-1145
18. Jeste DV, Okamoto A, Napolitano J, et al. Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am J Psychiatry 2000;157:1150-1155
19. Tollefson GD, Beasley CM Jr, Tamura RN, et al. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry 1997;154:1248-1254
20. Kinon BJ, Jeste DV, Kollack-Walker S, et al. Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods. Prog Neuropsychopharmacol Biol Psychiatry 2004;28:985-996
21. Spivak B, Mester R, Abesgaus J, et al. Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients. J Clin Psychiatry 1997;58:318-322
22. Sacchetti E, Valsecchi P. Quetiapine, clozapine, and olanzapine in the treatment of tardive dyskinesia induced by first-generation antipsychotics: a 124-week case report. Int Clin Psychopharmacol 2003;18:357-359
23. Conley RR, Kelly DL. Second-generation antipsychotics for schizophrenia: a review of clinical pharmacology and medication-associated side effects. Isr J Psychiatry Relat Sci 2005;42:51-60
24. Keck PE Jr, McElroy SL. Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic. Expert Opin Investig Drugs 2003;12:655-662
25. Grunder G, Kungel M, Ebrecht M, et al. Aripiprazole: pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia. Pharmacopsychiatry 2006;39(suppl 1):S21-S25
26. Hirose T, Uwahodo Y, Yamada S, et al. Mechanism of action of aripiprazole predicts clinical efficacy and a favorable side-effect profile. J Psychopharmacol 2004;18:375-383
27. Grunder G, Carlsson A, Wong DF. Mechanism of new antipsychotic medications: occupancy is not just antagonism. Arch Gen Psychiatry 2003;60:974-977
28. Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002;63:763-771
29. Pigott TA, Carson WH, Saha AR, et al. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry 2003;64:1048-1056
30. Kasper S, Lerman MN, McQuade RD, et al. Efficacy and safety of aripiprazole vs haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol 2003;6:325-337
31. Potkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003;60:681-690
32. Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003;61:123-136
33. Keck PE Jr, Calabrese JR, McQuade RD, et al. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry 2006;67:626-637
34. Vieta E, Bourin M, Sanchez R, et al. Effectiveness of aripiprazole v haloperidol in acute bipolar mania: double-blind, randomized, comparative 12-week trial. Br J Psychiatry 2005;187:235-242
35. Keck PE Jr, Marcus R, Tourkodimitris S, et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003;160:1651-1658
36. Nickel MK, Muehlbacher M, Nickel C, et al. Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. Am J Psychiatry 2006;163:833-838
37. De Deyn P, Jeste DV, Swanink R, et al. Aripiprazole for the treatment of psychosis in patients with Alzheimer's disease: a randomized, placebo-controlled study. J Clin Psychopharmacol 2005;25:463-467
38. Guy W, ed. ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education, and Welfare publication (ADM) 76-338. Washington, DC: National Institute of Mental Health; 1976:534-537
39. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia (letter). Arch Gen Psychiatry 1982;39:486-487
40. Owens DG. Involuntary disorders of movement in chronic schizophrenia-the role of the illness and its treatment. Psychopharmacology Suppl 1985;2:79-87
41. Chouinard G. Interrelations between psychiatric symptoms and drug-induced movement disorder. J Psychiatry Neurosci 2006;31:177-180
42. Gharabawi GM, Bossie CA, Zhu Y. New-onset tardive dyskinesia in patients with first-episode psychosis receiving risperidone or haloperidol. Am J Psychiatry 2006;163:938-939
43. Gourzis P, Polychronopoulos P, Papepetropoulos S, et al. Quetiapine in the treatment of focal tardive dystonia induced by other atypical antipsychotics: a report of 2 cases. Clin Neuropharmacol 2005;28:195-196
44. Tarsy D, Baldessarini RJ. Epidemiology of tardive dyskinesia: is risk declining with modem antipsychotics? Mov Disord 2006;21:589-598
45. Grant MJ, Baldessarini RJ. Possible improvement of neurolepticassociated tardive dyskinesia during treatment with aripiprazole. Ann Pharmacother 2005;39:1953
46. Csernansky JG, Mahmoud R, Brenner R, et al. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia [Erratum in: N Engl J Med 2002;346:1424]. N Engl J Med 2002;346:16-22
47. Beasley CM, Dellva MA, Tamura RN, et al. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. Br J Psychiatry 1999;174:23-30
48. Glazer WM, Morgenstern H. Pultz JA, et al. Incidence of persistent tardive dyskinesia may be lower with quetiapine treatment than previously reported with typical antipsychotics in patients with psychoses [abstract]. In: Proceedings of the 38th Annual Meeting of the American College of Neuropsychopharmacology; Dec 12-16, 1999; Acapulco. Mexico:271
49. Rein W. L'Héritier C. Treatment-emergent tardive dyskinesia in the long-term treatment of schizophrenia: a comparison of amisulpride and haloperidol [abstract]. J Eur Coll Neuropsychophannacol 1999;9:282
50. Argo TR, Carnahan RM, Perry PJ. Aripiprazole, a novel atypical antipsychotic drug. Pharmacotherapy 2004;24:212-228
51. Zacher JL, Hatchett AD. Aripiprazole-induced movement disorder. Am J Psychiatry 2006;163:160-161
52. Salmoiraghi A, Odiyoor M. A case of aripiprazole and extrapyramidal side effects. J Psychopharmacol 2006;20:592-593
53. Sajbel TA, Cheney EM, DeQuardo JR. Aripiprazole-associated dyskinesia. Ann Pharmacother 2005;39:200-201
54. Cohen ST, Rulf D, Pies R. Extrapyramidal side effects associated with aripiprazole co-prescription in 2 patients. J Clin Psychiatry 2005;66:135-136
55. Schonberger RB, Douglas L, Baum CR. Severe extrapyramidal symptoms in a 3-year-old boy after accidental ingestion of the new antipsychotic drug aripiprazole. Pediatrics 2004;114:1743
56. 3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology 2002;27:248-259
57. Casey DE. Pathophysiology of antipsychotic drug-induced movement disorders. J Clin Psychiatry 2004;65(suppl 9):25-28
58. 2 receptor mRNAs in rat brain. J Mol Neurosci 1990;2:155-161
59. Huang N, Ase AR, Hebert C, et al. Effects of chronic neuroleptic treatments on dopamine D1 and D2 receptors: homogenate binding and autoradiographic studies. Neurochem Int 1997;30:277-290
60. Sakai K, Gao XM, Hashimoto T, et al. Traditional and new antipsychotic drugs differentially alter neurotransmission markers in basal ganglia-thalamocortical neural pathways. Synapse 2001;39:152-160
61. 2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. Psychopharmacology (Berl) 2000;152:174-180
62. Tarazi FI, Zhang K, Baldessarini RJ. Long-term effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: implications for antipsychotic drug treatment. J Pharmacol Exp Ther 2001;297:711-717
63. 2 receptor occupancy and the vacuous chewing movement syndrome in rats. Psychopharmacology (Berl) 2003;165:166-171
64. Fields JZ, Drucker GE. Wichlinski L, et al. Neurochemical basis for the absence of overt "stereotyped" behaviors in rats with up-regulated striatal D2 dopamine receptors. Clin Neuropharmacol 1991;14:199-208
65. Inoue A, Miki S, Seto M, et al. Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum. EurJ Pharmacol 1997;321:105-111